Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05391126 · ClinicalTrials.gov registry record · NA
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
A NA study of Colorectal Cancer and Pancreatic Cancer, sponsored by Reema A. Patel.
- Recruiting
- Registry status
- NA
- Development phase
- 178
- Enrollment target
- 1
- Study location
NCT05391126 is a NA study of Colorectal Cancer and Pancreatic Cancer that is actively recruiting participants, run by Reema A. Patel. The registered enrollment target is 178 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05391126, a NA study of Colorectal Cancer and Pancreatic Cancer, is actively recruiting participants, sponsored by Reema A. Patel.
- RECRUITING
- Registry status
- NA
- Development phase
- 178 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, randomized study designed to compare genotype-guided dosing to usual care in patients with pancreas cancer and colorectal cancer who are UGT1A1 intermediate metabolizers (\*1/\*28) (heterozygotes) and usual UGT metabolizers (\*1/\*1). All patients will be assessed for UGT1A1 genotype at screening and those with intermediate or usual UGT1A1 genotypes (\*1/\*28, \*1/\*1) will be randomized to genotype-guided dosing versus usual care.
Conditions Studied
Interventions
- DRUG Irinotecan
Study Locations (1)
Kentucky
- University of Kentucky - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 178 participants |
| Start Date | 2022-09-28 |
| Est. Completion | 2027-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05391126
The ClinicalTrials.gov registry entry for NCT05391126 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 178 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (88% lower). The listed sponsor is Reema A. Patel, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Irinotecan is the first listed.
NCT05391126 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.
Frequently Asked Questions
What is clinical trial NCT05391126 about?
NCT05391126 is a clinical study titled "GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care". This is a prospective, randomized study designed to compare genotype-guided dosing to usual care in patients with pancreas cancer and colorectal cancer who are UGT1A1 intermediate metabolizers (\*1/\*28) (heterozygotes) and usual UGT metabolizers (\*1/\*1). All patients will be assessed for UGT1A1 g...
What is the current status of trial NCT05391126?
This trial is currently recruiting. It is a NA study. The enrollment target is 178 participants. The study started on 2022-09-28. Estimated completion is 2027-05.
What conditions does trial NCT05391126 study?
This clinical trial studies the following conditions: Colorectal Cancer, Pancreatic Cancer.
What interventions are being tested in trial NCT05391126?
The interventions under investigation include: Irinotecan (DRUG).
Who is sponsoring clinical trial NCT05391126?
This trial is sponsored by Reema A. Patel, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05391126 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
Resistance Exercise and Creatine in Colorectal Cancer
RECRUITING · NA
-
Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery
RECRUITING · NA
-
Ultrasound and Photoacoustic Imaging for Enhanced Differential Diagnosis of Rectal Cancer
RECRUITING · NA
-
Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.